about
CRIF1 interacting with CDK2 regulates bone marrow microenvironment-induced G0/G1 arrest of leukemia cellsPAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesisMultiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markersAdvances in complex multiparameter flow cytometry technology: Applications in stem cell research.Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.Cancer stem cell-directed therapies: recent data from the laboratory and clinic.Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.Targeting stem cells-clinical implications for cancer therapy.E- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft modelNeural regulation of hematopoiesis, inflammation, and cancer.The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia developmentThe mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells.CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progressionPrognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemiaMinimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia.Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.A preclinical evaluation of antimycin a as a potential antilung cancer stem cell agent.Targeting the leukemic stem cell: the Holy Grail of leukemia therapyNew wirings in the survivin networks.Differential regulation of myeloid leukemias by the bone marrow microenvironment.Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase.Mechanisms of resistance to FLT3 inhibitors.Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cellsAcute myelogenous leukemia switch lineage upon relapse to acute lymphoblastic leukemia: a case report.Glioma stem cell research for the development of immunotherapy.Properties and feasibility of using cancer stem cells in clinical cancer treatment.Docosahexaenoic acid induces dose dependent cell death in an early undifferentiated subtype of acute myeloid leukemia cell lineUpregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion.NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia.Acute myeloid leukemia stem cells: seek and destroy.The versatility of haematopoietic stem cells: implications for leukaemia.Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.Recent advances in acute myeloid leukemia stem cell biologyRoles of p53 in various biological aspects of hematopoietic stem cells.TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.The versatile landscape of haematopoiesis: are leukaemia stem cells as versatile?TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
P2860
Q24336990-363C36B6-39BC-4ABC-9169-8B27C15E1907Q28302461-7F3AD3BB-9EB3-4D2F-A3CD-421FC4442B4AQ28749547-753DCAB3-DC6C-45A0-913F-5C65FE868399Q30479710-B99E2482-2BA3-412E-812F-22D53F3B0D9BQ31147913-FDD10A9C-6338-465A-9A01-D352D2F33259Q33391372-0B911BF9-8EE6-4BFD-8CCD-2F07BD539716Q33823577-6B5202C2-7198-4ACE-99C3-20645ACC2183Q34253081-E1AD1907-A4AC-4CCB-9F5B-5CA57B0E8B0CQ34555251-0ECF7217-2309-4794-9919-332B2EB4DD17Q34906157-25099DEF-6890-4881-84C5-D34ECAA68D5BQ35560457-BA5DB5FC-C456-46EC-9786-6A95E8C9712EQ35561510-8E83F0E0-83AF-4061-BDC7-0AFC3A0CC37FQ35664319-5086FE2D-85E3-4B01-925F-C29AED305DEEQ35698863-20332238-54AC-4294-9F3A-B91750F8F91EQ35803001-D4A21B2B-3FB0-4DA3-8C8C-541E148A45BBQ35992927-C8158AFC-A35C-47CF-B051-B16D64A5957FQ36765731-A7340972-BA3F-4983-B35A-35C1912DC23CQ36926120-6A4BA723-7CE7-4FD0-9452-E353AEF4D750Q36955985-B1C424F8-CB3E-4F0E-A70C-1336EB3AD45FQ37272565-11A3679B-9EC9-41CD-9355-30C36B353FCAQ37302750-D84EB336-384F-4CF9-A09F-D271D9B89C23Q37308308-96DEC230-5E57-438A-AEC2-9B7D7973F6F9Q37317718-E74542EB-0108-4C0A-8455-DE5B880ED402Q37375423-3C6E93CF-8A2E-456F-AAB9-2F7E2F9B497AQ37406808-F2EAE1BC-2828-4B9D-958D-B1AEACF2259BQ37437567-1B4A3DC8-F14F-49CD-ABC0-6F997B9FAC93Q37452665-076701FB-A01E-487C-9ECB-EB40E316FDA9Q37596687-ECA2741D-34A2-4C6E-A877-FA52D7DC2FDAQ37637146-F330BC77-CD06-4320-A9A4-64FA850D0CCCQ37718496-5E1FA7D4-0693-4285-BF78-087FCF9CAC4AQ37729001-09B62EB4-1470-4899-A278-FB9094845F08Q37810086-9787091F-F86B-430D-B794-99DA11A6870EQ37823589-4A6CA15B-FB31-4A4A-8FCB-9BD5F15F6EF5Q37850824-86AFA3F5-971A-4EEC-B0B7-719ACEB88DA9Q37978771-115339E8-1143-4D02-B8D4-F08694516168Q38003359-4EB09EE8-C1C0-43A4-B077-C38A69589814Q38025085-29ACBA79-8AFD-4E17-91FB-C6BEF8CCD3B7Q38035447-705A6B21-89E8-4744-A35A-932D37CBA701Q38059885-BC1D1938-6667-4DB2-A849-10C01824B8B4Q38138901-75601498-090F-44EF-B323-2E759A843F2E
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Right on target: eradicating leukemic stem cells.
@ast
Right on target: eradicating leukemic stem cells.
@en
type
label
Right on target: eradicating leukemic stem cells.
@ast
Right on target: eradicating leukemic stem cells.
@en
prefLabel
Right on target: eradicating leukemic stem cells.
@ast
Right on target: eradicating leukemic stem cells.
@en
P2860
P1476
Right on target: eradicating leukemic stem cells.
@en
P2093
Daniela S Krause
Richard A Van Etten
P2860
P304
P356
10.1016/J.MOLMED.2007.09.003
P577
2007-11-05T00:00:00Z